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ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a feared entity that occurs most frequently in conditions of extreme 
immunodeficiency. The diagnosis is often made long after the onset of symptoms due to the physicians’ unfamiliarity, 
and the unavailability of diagnostic tests in some medical centers. Although the incidence of PML is decreasing among 
HIV patients with the advent of highly active antiretroviral therapy (HAART), in Brazil this entity is the fourth highest 
neurological complication among these patients. The authors present the case of a middle-aged man who tested positive 
for HIV concomitantly with the presentation of hyposensitivity in the face and the right side of the body, accompanied 
by mild weakness in the left upper limb. The clinical features worsened rapidly within a couple of weeks. The diagnostic 
work-up pointed to the working diagnosis of PML after brain magnetic resonance imaging; however, the detection of 
the John Cunningham virus (JCV) in the cerebral spinal fluid was negative. HAART was started but the patient died after 
7 weeks of hospitalization. The autopsy revealed extensive multifocal patchy areas of demyelination in the white matter 
where the microscopy depicted demyelination, oligodendrocytes alterations, bizarre atypical astrocytes, and perivascular 
lymphocytic infiltration. The immunohistochemistry was positive for anti-SV40, and the polymerase chain reaction of the 
brain paraffin-embedded tissue was positive for JCV. The authors highlight the challenges for diagnosing PML, as well 
as the devastating outcome of PML among HIV patients. 
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CASE REPORT
A 43-year-old man presented to the emergency 
room complaining of tongue paresthesia, slurred 
speech, and weakness. These symptoms had developed 
insidiously and progressively over the past 4 weeks. 
The patient described muscular weakness initially 
involving the left side of the body, which soon included 
the right side. He also referred a decrease in sensitivity 
in the left half of the body. He denied fever, headache, 
weight loss, dyspnea, convulsions, visual symptoms, 
incontinence, and vertigo. His past medical history was 
unremarkable, except for smoking (15 pack-years) and 
recreational alcohol consumption.
The neurological  examination revealed a 
hyposensitivity in the right hemiface, as in the right 
half of the body, and grade 4 of muscle strength 
of the left upper limb. The remaining physical 
examination was normal as were his vital signs. 
The initial laboratory work-up was normal; however, 
further investigation revealed a positive serology for 
HIV infection by the enzyme-linked immunosorbent 
assay and Western blotting. The TCD4+ peripheral 
count was 75 cells/µL, and the HIV-1 RNA viral load 
in the blood was 97,911 copies/mL (branched DNA) 
or Log 4991. The brain computed tomography (CT) 
revealed two hypodense foci in the right cerebral 
hemisphere’s white matter, in the right frontal lobe, 
and in the high parietal region, without contrast 
enhancement or midline shift.
Due to the imaging findings in a patient with 
HIV, neurotoxoplasmosis was the initial working 
diagnosis. Therefore, pyrimethamine and sulfadiazine 
were promptly prescribed. Two weeks later, this 
antibiotic regimen was withdrawn since (i) the 
patient’s clinical features did not improve; (ii) the 
serology for toxoplasmosis tested negative for 
immunoglobulin IgG and IgM; and (iii) the lesions 
increased in size and became more evident in 
controlled CT. The brain magnetic resonance imaging 
(MRI) showed extensive discontinuous hyper signal 
areas on T2- and FLAIR-weighted images in the 
hemispheric white matter, with predominance in the 
right frontotemporal subcortical region, as well as in 
the splenium of the corpus callosum and the brainstem 
(Figure 1). These findings raised the diagnosis of PML. 
At this time, the cerebrospinal fluid (CSF) examination 
showed leukocytes of 2 cells, erythrocytes of 14 cells, 
protein of 25 mg/dL, and glucose of 58 mg/dL. 
CSF culture was negative for bacteria, mycobacteria, 
and fungus. The polymerase chain reactions (PCR) 
for Mycobacterium tuberculosis, Cryptococcus spp, 
Toxoplasma gondii, and JCV were negative, which 
permitted the initiation of highly active antiretroviral 
therapy (HAART).
The patient’s outcome was troublesome with 
progressive worsening of his neurological status, 
and slow progression to spastic paraparesis. At the 
end of the fourth week of hospitalization the patient 
maintained only the distal movement of the right 
upper limb, hyperreflexia, tetraplegia in a pyramidal 
pattern, generalized spasticity and hypertonia, 
ophthalmoplegia, facial amimia, gaze fixation inability, 
Figure 1. Brain MRI. A – T2 weighted axial image 
demonstrates subcortical e periventricular white matter 
lesions in the right hemisphere, without significant 
associated mass effect; B – Flair weighted axial image 
shows subcortical confluent lesions on the right 
temporal lobe, internal capsule and thalamus; C – Flair 
weighted axial image shows pontine and right middle 
cerebellar peduncle confluent lesions; D – Post contrast 
T1 weighted coronal image demonstrates lack of 
contrast enhancement in the aforementioned described 
lesions.
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anarthria, and the inability to swallow. According to this 
outcome, the diagnosis of PML was highly considered, 
and because of the deterioration of the neurological 
status concomitantly after HAART, the hypothesis of 
immune reconstitution inflammatory syndrome-PML 
(IRIS-PML) was considered. Thus, prednisone 1 mg/kg 
was started. However, no improvement was observed.
Meanwhile, the patient presented an episode of 
bronchoaspiration and septic shock, and died after 7 
weeks of hospitalization.
An autopsy was performed after the informed 
consent signed by his wife.
AUTOPSY FINDINGS
The examination of the central nervous system 
(CNS) showed vascular congestion in the meninges 
with mild cerebral edema (Figure 2A). The vessels 
of the circle of Willis were preserved (Figure 2B). 
The coronal section depicted small, irregular, and 
ill-defined brownish patches involving the white 
matter and the basal ganglia. These lesions were more 
prominent in the right hemisphere, where the patches 
in the subcortical topography became confluent 
(Figures 2C, 2D, and Figure 3).
Figure 2. Gross findings of the brain. A – Vascular congestion in the meninges and generalized edema characterized 
by flattened gyri and narrowed intervening sulci; B – Inferior and posterior view showing edema, but without signals 
of herniation. The circle of Willis vessels were preserved; C – Coronal section of the brain showing small, irregular, 
and ill-defined brownish patches of white matter, also compromising the basal ganglia; D – Presence of poorly 
defined areas of brownish patches in the subcortical topography, which became confluent plaques in the white 
matter, especially in the right parieto–occiptal hemisphere.
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On microscopy, the boundary between the 
gray and the white matter was blurred by chronic 
inflammatory infiltrate with an increase in the number 
of oligodendrocytes, which showed typical glassy 
chromatin nuclei of viral inclusion. In the white matter, 
the parenchyma was disrupted by a dense infiltration 
of foamy macrophages, reactive astrocytes (which 
sometimes had bizarre atypical appearance), and 
perivascular lymphocytic inflammation (Figure 4).
The immunohistochemistry study was positive 
for simian virus 40 (SV40) (clone MRQ-4, Cell 
Marque), which cross-reacts with polyomavirus 
(Figure 5), and was negative for cytomegalovirus and 
herpesvirus. The presence of the JC polyomavirus 
(JCPyV) was also detected in the formaldehyde-fixed, 
paraffin-embedded, CNS by the specific amplification 
of genetic material from the DNA sample. For this 
purpose, the primers described by Agostini et al.1 were 
used along with DNA isolates from samples previously 
known as positives and negatives. Thus, the presence 
of genetic material of JCPyV in the neural tissue of the 
patient was assured.
The  l ungs  we re  conges ted  and  heavy . 
The microscopic examination revealed a diffuse alveolar 
edema and bronchopneumonia, possibly secondary 
to bronchoaspiration (Figure 6A). The pancreas 
examination showed necrosis and steatonecrosis 
(Figure 6B), while the kidney’s histology presented 
acute tubular necrosis—the findings of which were 
consistent with a final outcome due to hemodynamic 
shock. There was also zone 3 passive congestion in liver 
parenchyma. Another finding related to AIDS was the 
splenic white pulp lymphocytic depletion (Figure 6C) 
and a focal chronic inflammatory infiltration in adrenal 
parenchyma (Figure 6D).
DISCUSSION
Progressive multifocal leukoencephalopathy 
(PML) is a severe demyelinating disease of the CNS 
characterized by injury to the glial cells—in particular, 
the oligodendrocytes—caused by a polyomavirus called 
JCV. PML mostly occurs in immunosuppressed patients, 
and presents with a progressive, disabling, and often 
fatal clinical course. Since the HIV epidemic and the 
emergence of new immunosuppressive drugs, PML has 
become a significant source of concern and research.2,3
In the 1950s, the cytotechnologist, Andrew Ricci, 
initially observed cells with large homogeneous nuclei 
in the urine, which he christened the “decoy cells” 
because of their benign origin mimicking cancer cells. 
The nature of the “decoy cells” was clarified in 1971 
when Gardner et al.4 isolated the human polyomavirus 
from the urine of a renal transplant recipient with 
initials BK.5 This virus is a non-enveloped DNA viral 
group that belongs to the Polyomaviridae family, 
which infects humans, as well as apes, rodents, and 
parakeets. In humans, the infection is caused by the 
Figure 3. Gross examination of the cutting surface of the brain. A and B – Coronal section showing in detail the 
ill-defined brownish patches to confluent plaques in the white matter, with poorly defined limits between gray and 
white matter.
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Figure 4. Photomicrographs of the brain. A – The limit between gray and white matter was blurred by chronic 
inflammatory infiltrate with augmented oligodendrocytes (H&E 100X); B – White matter parenchyma with dense 
infiltration of foamy macrophages, reactive astrocytes, and perivascular lymphocytic inflammation (H&E 200X); 
C – Detail of the reactive astrocytes showing bizarre atypical nuclei (H&E 400X); D – Gray matter with augmented 
oligodendrocytes showing typical glassy chromatin nuclei of viral inclusion (H&E 400X).
Figure 5. Photomicrographs of the brain. A and B – Immunophenotype positive for simian virus 40 highlighting the 
cells infected by the JCV. (Immunohistochemistry 400X).
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BK virus, which is associated with nephropathy in 
transplanted recipients, and JCV, which causes PML.6
The JCV is distributed worldwide with a prevalence 
of 50-70%.7-9 The transmission occurs through the 
fecal-oral and respiratory routes, and by tissue donation. 
The polyomavirus causes a latent asymptomatic 
infection with a persistent cycle of replication, which 
contributes to the spread of the virus. The replication 
cycles are associated with fluctuations of the immunity 
status, such as pregnancy and senility, or with severe 
immunosuppression, which occurs after transplant, 
chemotherapy, or HIV infection.
Rare cases of PML in immunocompetent patients 
with or without an underlying disease have been 
reported.10 Those with an underlying disease have been 
defined as PML in the presence of occult or transient 
immunosuppression, namely (i) hepatic cirrhosis; 
(ii) chronic renal failure; (iii) pregnancy; (iv) dementia; 
and (v) dermatomyositis.11 Thus, PML should be 
considered in the differential diagnosis of patients with 
new-onset neurological symptoms, even without overt 
immunosuppressive risk factors.
Over the years, the origin of the underlying 
immunosuppression has been changing because of 
the improvement in HIV treatment, and the emergence 
of new and widely used immunosuppressive drugs. 
A recent study on the incidence of PML in Sweden 
over 3 decades showed that HIV infection was the 
leading cause of immunosuppression in the first fifth 
(1988-1992) of the study period, representing 48% of 
Figure 6. Photomicrographs. A – Lung: pulmonary parenchyma showing bronchopneumonia and diffuse alveolar 
edema (H&E 100X); B – Pancreas: parenchyma showing diffuse ischemic necrosis with focal steatonecrosis 
(H&E 100X); C – Spleen: presence of white pulp lymphocytic depletion (H&E 100X); D – Adrenal: presence of focal 
chronic inflammatory infiltration in adrenal parenchyma (H&E 100X).
Lopes CCB, Crivillari M, Prado JCM, et al.
7-11Autops Case Rep (São Paulo). 2019;9(1):e2018063
cases of PML. However, in the last fifth of the study 
period (2008-2013), the autoimmune diseases took the 
lead (39% of the cases), while HIV infection dropped 
to 11%.12 Similarly, other studies showed a decline in 
the incidence of PML among HIV patients in Denmark13 
and Switzerland.14
Despite this declining incidence, PML remains a 
significant CNS complication of patients with HIV/AIDS. 
A Brazilian study showed that PML was the fourth most 
frequent opportunistic infection in AIDS patients after 
toxoplasmosis, cryptococcal meningoencephalitis, and 
neurotuberculosis.15
Clinically, PML can present a broad constellation 
of neurologic signs and symptoms due to its ability to 
affect virtually any area of the brain, and the frequently 
multifocal nature of the lesions.2,3 Thus, it is difficult 
to establish a topographic neurological diagnosis, 
similar to that which occurs with other demyelinating 
diseases. The most common clinical features comprise 
motor weakness (hemiparesis or monoparesis), 
cognitive dysfunction, appendicular or gait ataxia, 
visual symptoms (hemianopsia, diplopia), and speech 
disturbances. Sensory loss, seizures, headache, and 
aphasia occur less frequently.12,13,15,16 In our case, the 
patient presented with motor weakness, impaired 
gait, speech disturbance, and sensory loss, which were 
consistent with the most cited features of PML.
Based on the CT images and the positive result 
for HIV tests, neurotoxoplasmosis was the initial 
working diagnosis because of its leading cause of 
CNS infection in AIDS patients. The current treatment 
for neurotoxoplasmosis is highly effective and is 
accompanied by a rapid clinical recovery. In a large 
clinical series of patients,17 74% showed improved 
in their symptoms by day 7 of therapy, and 91% of 
them by day 14. Thus, it is reasonable to conclude that 
the failure of toxoplasmosis treatment should raise 
the suspicion for other differential diagnoses. In our 
case, the therapeutic failure after 2 weeks, which was 
associated with the negative serology for toxoplasmosis, 
made the diagnosis of neurotoxoplasmosis unlikely, 
and the suspicion for PML increased.
With the increase in knowledge regarding PML, 
and the new techniques that help to diagnose JCV, 
new forms of CNS involvement and, therefore, new 
forms of clinical syndromes (hitherto not well-known) 
have been described; such as (i) JCV granule cell 
neuropathy leading to a cerebellar syndrome; (ii) JCV 
encephalopathy due to cortical grey matter impairment; 
and (iii) JCV meningitis, which leads to meningeal 
syndrome without evidence of brain lesions.2,3
The diagnosis of PML faces some obstacles, such 
as its low incidence, the unfamiliarity of it among most 
physicians, and the eventual unspecificity of the clinical 
features and neuroimaging. The latter may mimic 
stroke, brain tumor, or cerebral toxoplasmosis, which 
often retard the diagnosis. In a retrospective study 
involving 111 PML cases,18 the median time from the 
initial symptoms to diagnosis was 74 days. In this study, 
misdiagnoses were done in nearly two-thirds of cases, 
and more than three-quarters of patients had their 
diagnosis delayed for more than 1 month. To avoid 
this delay, the inclusion of PML in the differential 
diagnosis of CNS lesions in patients with known risk 
factors together with early work-up directed towards 
this entity seems to be the better procedure.
In 2013, the Neuroinfectious Disease Section 
of the American Academy of Neurology proposed 
the criteria9 to establish the diagnosis of PML. PML 
diagnosis is considered to be definitive by (i) securing 
the diagnosis with tissue sample; or (ii) determining 
the diagnosis with compatible clinical and radiographic 
features coupled with the demonstration of the virus 
in CSF. A lack of one or more of the aforementioned 
findings alters the diagnostic characterization to 
probable or possible. Therefore, in our case, the in vivo 
diagnosis of PML was considered possible due to the 
lack of demonstration of JCV in the CSF.
The diagnosis based on neuropathology usually 
is not that difficult if the specimen shows the 
demyelination, the hyperchromatic and enlarged 
oligodendroglial nuclei, and the enlarged bizarre 
astrocytes with lobulated hyperchromatic nuclei 
accompanied by the detection of JCV.9 However, 
the arduous task relies on obtaining the brain tissue. 
Although brain biopsy has been proved to be an 
effective way of diagnosing intracranial lesions, it 
requires a highly-specialized team and costly resources. 
The procedure is associated with a significant risk of 
fatal complications and a high index of morbidity. 
Moreover, the lesions may not be readily accessible, 
the biopsy size may be insufficient, and sometimes the 
patient’s clinical status does not allow the procedure 
to be undertaken.19-21
The detection of JCV in the brain tissue of PML 
may be achieved by immunohistochemistry (IHC) 
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using commercially anti-SV40 monoclonal antibody, 
in situ hybridization (ISH) and PCR. Zivanovic et al.21 
reported the comparison of these three methods in a 
series of seven cases (four biopsies and four autopsies; 
one case had biopsy and was autopsied as well) and 
concluded that ISH was the more sensitive method 
followed by PCR and IHC, and recommended using 
a combination of at least two different methods 
for JCV detection. Muñoz-Mármol et al.,22 studying 
14 paraffin-embedded postmortem brain specimens, 
showed better sensitivity for IHC and PCR. In this series, 
the IHC was more sensitive for the PAb 2003 antibody 
compared to the antibody anti-SV40.
In our case, in vivo brain biopsy was unavailable 
and the definitive diagnosis of PML was made by 
postmortem tissue analysis. Along with the typical 
gross findings in autopsy, the microscopy was rich 
and consistent with the typical descriptions of the 
JCV histological findings. The IHC with anti-SV40 
and the PCR were positive in the CNS tissue sample. 
It is worth pointing out that the number of altered 
oligodendroglial cells were high, which increased the 
chances of detecting the virus by using the different 
methods.
Because of the cited obstacles for performing 
brain biopsy, the diagnosis of PML commonly relies on 
the analysis of the CSF. However, the PCR for JCV is 
not widely available in some medical centers, and its 
sensitivity decreases with HAART. Marzocchetti et al.23 
compared the sensitivity of JCV by PCR in the CSF of 
HIV patients with suspected PML between 1992 and 
2002, and found a drop in the positive detection from 
89.5% in the pre-HAART era (1992-1995) to 57.5% 
in the HAART era (1996-2002), but no changes in the 
specificity were observed. Similarly, this discrepancy 
concerning the sensitivity of PCR tested in the CSF was 
observed comparing the studies of McGuire et al.24 
and Bossolasco et al.25 The former found a sensitivity 
of 92% in the pre-HAART era (1995) and the latter 
found 76% in the HAART era (2005).
The radiologic investigation helps to make the 
diagnosis and may allow its distinction from other 
diagnoses.9 MRI is the most appropriate examination 
for PML work-up since it detects early lesions. PML 
lesions appear as hyperintense areas in T2-weighted 
and fluid-attenuated inversion recovery (FLAIR) images, 
and as hypointense areas in T1-weighted images. In CT 
scans, brain lesions appear as asymmetric multifocal 
areas of hypodensity. These lesions are frequently 
asymmetric, bilateral, and multiple, although they 
may occasionally be solitary, with variable shape and 
size, which become confluent and extensive with the 
progression of the disease. They are mainly subcortical 
and are located almost exclusively in the white matter, 
although eventual extension to the gray matter has 
been reported. Usually, there is no mass effect even in 
the extensive lesions, nor contrast enhancement.9,26-28
As reported in our case, the hypodense brain 
lesions found in the CT were non-specific, and did not 
add any information to achieve the final diagnosis. 
Neurotoxoplasmosis was assumed as the working 
diagnosis even in the absence of the typical contour 
contrast enhancement. Indeed, this finding may be 
absent or faint when CD4 is below 50 cells/mm3.29 
In fact, the diagnosis of PML was highly considered 
after the MRI despite the negative PCR for JCV result 
in CSF.
Several therapeutic regimens including cytarabine, 
camptothecin, topotecan, and cidofovir were studied 
and proposed as the PML treatment. These drugs 
have an anti-JCV replication action in vitro; however, 
the in vivo results were disappointing.3 The serotonin 
receptor blocker was also tested after the discovery of 
the interaction between JCV and serotonin receptors 
5-HT-2a from glial cells.2 Nonetheless, no statistical 
significance in 1-year survival was observed between 
patients treated with mirtazapine and a control 
group.30 Thus, no specific, effective treatment for JCV 
is currently available. The most effective therapy for 
PML relies upon the early onset of HAART.31
One of the management challenges of PML 
and other infections associated with AIDS remains 
the identification of the immune reconstitution 
inflammatory syndrome (IRIS), which is characterized 
by clinical deterioration, despite virological clearance, 
usually within 4-8 weeks after the HAART outset. 
The pathophysiology of IRIS is not yet fully understood, 
but seems to be attributed to an exacerbated 
inflammatory response modulated by the presence 
of the opportunistic agent or its antigens. In the 
context of PML, IRIS can occur both in its “unmasking” 
form—when the previously asymptomatic patient begins 
to present symptoms after HAART prescription—or in its 
“paradoxical” form, which arises during or after PML’s 
treatment, when new clinical symptoms or worsening 
of the pre-existing symptoms arise. The latter often 
raises doubts as to whether there is a progression of 
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PML or if it corresponds to an overlap with IRIS, along 
with the possibility of HAART’s adverse effects.32
The diagnosis of IRIS should be suspected 
whenever the clinical features of PML worsen or start 
4-8 weeks after the introduction of HAART, and the 
CD4+ is <100 cell/mm3 before the onset of HAART; or 
when an immune or virological response is observed 
after the HAART onset. In the case presented herein, 
IRIS was suspected because the neurological worsening 
coincided with the third week of HAART.
The diagnosis or suspicion of IRIS should not 
motivate the withdrawal of HAART. Untreated HIV 
patients with the diagnosis of PML show an increment in 
survival rate with HAART from 10% to 43-75%.33-35 The 
management of IRIS consists of using a non-steroidal 
anti-inflammatory drug in mild cases, or prednisone at a 
dose of 1-2mg/kg, or equivalent, for 1-2 weeks in more 
severe cases. However, the use of anti-inflammatory 
agents to treat PML-IRIS remains debatable. A French 
review32 showed that corticosteroid therapy did not 
change the outcome of patients with PML-IRIS, and 
suggested that the corticosteroid prescription should 
be reserved for patients with severe neurological 
symptoms and/or massive cerebral inflammation, 
or brain herniation. In our case, prednisone was 
prescribed due to severe neurological worsening, but 
no improvement was observed.
The clinical course of PML remains dreadful. 
However, the survival rate has improved over the years, 
which is probably related to the growing efficacy of 
HAART. In the pre-HAART era, Berger et al.33 reported 
a median survival of 6 months for AIDS-related PML, 
and only in 9% did the survival exceeded 1 year. 
In the Danish cohort study,13 the median survival time 
increased from 0.4 years in those diagnosed with PML 
before 1997 (pre-HAART era) to 1.8 years in those 
diagnosed with PML from 1997 to 2006. Despite the 
increment in the survival rate after HAART, most PML 
survivors present sequelae. In our case, the disease 
followed the progressive course without any remission 
period, leading to a fatal outcome approximately 
3 months after the initial symptoms.
CONCLUSION
Although PML is rare, clinicians should always keep 
this possibility in mind while working up diseases with 
a similar clinical presentation. Every immunosuppressed 
patient with CNS injury should include PML in the 
diagnostic process. A CT scan is non-specific and 
unreliable, and it may delay or mask the diagnosis. 
Therefore, MRI should—whenever possible—be 
requested, since it may be the primary diagnostic clue. 
Tissue samples accompanied by immunopathological 
and molecular studies should always be pursued 
to reach a definitive diagnosis. Nevertheless, much 
remains to be discovered and researched concerning 
PML and other polyomavirus-related diseases, as well 
as their best treatment.
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